MarginsXMarginsX
Home › Markets › Health Care › RYTM

Rhythm Pharmaceuticals Inc. (RYTM)

RYTM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$107.48
-6.56% on the day
Market cap
$7.5B
Mid cap
Revenue · 2025
$189.8M
+45.8% on 2024
Net income · 2025
-$196.5M
-103.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1649904/000162828026012399/0001628280-26-012399-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerRYTM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2017
SEC CIK0001649904
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$189.8M
Net income-$196.5M
Operating income-$192.0M
Net margin-103.6%
Operating margin-101.2%
Revenue growth+45.8%
Cash$54.3M
Total assets$480.2M
P/E (computed)Net income was not positive
P/S (computed)39.3×

Warning signs

Cash runway
5.9 months
$40.0M cash at September 30, 2026
Share count, 1 year
+3.9%
2025-10-31 to 2026-11-02 · +17.3% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$41.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$40.0M cash; operating cash flow -$20.4M a quarter.Report 2026-09-30
Shares outstanding69,330,906 (2026-11-02); 66,736,056 a year earlier; 59,096,454 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-02-26
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $41.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$92.1M-$41.4M-$3.1M$40.0M$102.7M$280.7M10-Q 2026-11-03
Q2 2026
2026-06-30
$71.3M-$49.3M-$9.2M$65.6M$106.1M$239.9M10-Q 2026-08-04
Q1 2026
2026-03-31
$60.1M-$55.6M-$44.2M$62.1M$108.5M$217.2M10-Q 2026-05-05
Q4 2025
2025-12-31
$57.3M-$47.5M-$25.4M$54.3M$108.2M$189.8M10-K 2026-02-26
Q3 2025
2025-09-30
$51.3M-$52.9M-$26.6M$52.1M$109.0M$174.3M10-Q 2026-11-03
Q2 2025
2025-06-30
$48.5M-$46.6M-$23.3M$135.6M$109.8M$156.3M10-Q 2026-08-04
Q1 2025
2025-03-31
$32.7M-$49.5M-$40.4M$106.1M$109.5M$136.9M10-Q 2026-05-05
Q4 2024
2024-12-31
$41.8M-$43.3M-$18.8M$89.1M$109.8M$130.1M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-02-26
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-03
Latest current report8-K2026-11-03
Latest proxyDEFA14A2026-05-29

Source: SEC EDGAR submissions feed, 837 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.4%
1 month+32.8%
3 months-0.9%
Year to date+7.5%
1 year+19.9%
From 52-week high-2.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CYTKCytokinetics Incorporated$53.17-5.27%$7.4B
KNSAKiniksa Pharmaceuticals International plc$94.23-2.18%$7.4B
AMRXAmneal Pharmaceuticals Inc.$21.23-0.70%$7.4B
CORTCorcept Therapeutics Incorporated$69.22-5.10%$7.6B
ABVXAbivax SA$83.61-4.53%$7.3B
AXSMAxsome Therapeutics Inc.$137.01-3.30%$7.2B
ALKSAlkermes plc$46.53-1.06%$7.8B
PTGXProtagonist Therapeutics Inc.$124.83-4.67%$8.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier